<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg"/></p>
<p>在一次重大領導層變動中，西維斯（CVS Health）任命資深高管大衞·喬納（David Joyner）為新 CEO，接替卡倫·林奇（Karen Lynch）。</p>
<p>這一決定是因為西維斯正面臨着重大的利潤困境，受到醫療成本上升和其零售藥店消費下降的影響。</p>
<p>該消息是在週五發佈的，此前西維斯股價今年已經下跌近 20%，在領導層變動披露後的盤前交易中暴跌 13%。</p>
<p>該公司一直在應對其保險部門 Aetna 的挑戰，高於預期的醫療成本對盈利能力造成了壓力。</p>
<p>今年 8 月，西維斯下調了全年利潤預期，並透露計劃在未來幾年削減 20 億美元的成本，以穩定其財務表現。</p>
<h2>西維斯股票：公司稱醫療效益比為 95.2%</h2>
<p>在最新的聲明中，西維斯為第三季度提供了指引，預計調整後的每股收益在 1.05 美元至 1.10 美元之間。</p>
<p>該公司還提到了預期的醫療效益比為 95.2%，由於其醫療保健部門持續面臨成本壓力，高於先前預期。投資者被告知不要依賴先前的盈利指引，考慮到公司醫療福利部門持續承受的壓力。</p>
<p>西維斯計劃於 11 月 6 日發佈其第三季度財報，這是投資者期待更多瞭解公司財務方向的關鍵日期。</p>
<p>此次領導層變動是受到西維斯的主要股東 Glenview Capital 的不斷施壓而進行的，後者一直在倡導對公司進行重大改變。</p>
<p>上個月也有報道稱，西維斯董事會正在與戰略顧問合作，探討各種選項，包括潛在分拆其保險和零售部門。</p>
<p>大衞·喬納此前曾領導西維斯的藥房服務，擔任西維斯凱瑪克（CVS Caremark）總裁，預計他將為 CEO 角色帶來深厚的行業專業知識。</p>
<p>喬納在 Aetna 的藥品福利部門開始了他的職業生涯，並在西維斯內擔任過多個高級領導職位。</p>
<p>他的任命被視為一項戰略舉措，旨在引領公司度過當前的挑戰並釋放未來價值。</p>
<p>董事長羅傑·法拉表示：“我們相信大衞對我們綜合業務的深刻理解將使我們能夠應對我們行業面臨的挑戰，並加速所需的運營改進。” 法拉將擔任執行董事長。</p>
<p>卡倫·林奇辭去 CEO 職務後，也從公司董事會辭職。</p>
<p>喬納將作為領導層過渡的一部分加入董事會。</p>
<p>在西維斯努力恢復投資者信心和提高盈利能力的同時，喬納領導下的新領導層旨在引領公司度過這一關鍵的轉型階段。</p>
<p>文章來源：Invezz，西維斯股價下跌 13%，公司用大衞·喬納取代 CEO 卡倫·林奇</p>

西維斯

<p>西維斯健康已任命大衞·喬納（David Joyner）為首席執行官，接替卡倫·林奇（Karen Lynch），此舉發生在公司利潤嚴重下滑和股價下跌 13% 的背景下。這次領導層變動是在股價今年下跌近 20% 的情況下進行的，原因是醫療成本上升和消費者支出減少。西維斯已經削減了全年利潤預期，並計劃削減 10 億美元的成本。喬納此前擔任西維斯 Caremark 的總裁，預計他將利用自己在行業中的專業知識來應對公司面臨的挑戰。西維斯將於 11 月 6 日發佈第三季度財報，對投資者來説至關重要</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2022/04/132892091-m.jpg"/></p>
<p>In a major leadership shift, CVS Health has named longtime executive David Joyner as its new CEO, replacing Karen Lynch.</p>
<div class="lb-trans"><p>在一次重大領導層變動中，西維斯（CVS Health）任命資深高管大衞·喬納（David Joyner）為新 CEO，接替卡倫·林奇（Karen Lynch）。</p>
</div><p>The decision comes as CVS faces significant profit struggles, driven by rising medical costs and a drop in consumer spending at its retail pharmacies.</p>
<div class="lb-trans"><p>這一決定是因為西維斯正面臨着重大的利潤困境，受到醫療成本上升和其零售藥店消費下降的影響。</p>
</div><p>The announcement, made on Friday, follows a nearly 20% decline in CVS shares this year, with the stock plunging 13% in premarket trading after the leadership change was disclosed.</p>
<div class="lb-trans"><p>該消息是在週五發佈的，此前西維斯股價今年已經下跌近 20%，在領導層變動披露後的盤前交易中暴跌 13%。</p>
</div><p>The company has been grappling with challenges in its insurance unit, Aetna, where higher-than-expected medical costs have weighed on profitability.</p>
<div class="lb-trans"><p>該公司一直在應對其保險部門 Aetna 的挑戰，高於預期的醫療成本對盈利能力造成了壓力。</p>
</div><p>In August, CVS cut its full-year profit guidance and revealed plans to trim $2 billion in costs over the next few years to stabilize its financial performance.</p>
<div class="lb-trans"><p>今年 8 月，西維斯下調了全年利潤預期，並透露計劃在未來幾年削減 20 億美元的成本，以穩定其財務表現。</p>
</div><h2>CVS stock: company cites medical benefit ratio of 95.2%</h2>
<div class="lb-trans"><h2>西維斯股票：公司稱醫療效益比為 95.2%</h2>
</div><p>In its latest statement, CVS provided guidance for the third quarter, forecasting adjusted earnings between $1.05 and $1.10 per share.</p>
<div class="lb-trans"><p>在最新的聲明中，西維斯為第三季度提供了指引，預計調整後的每股收益在 1.05 美元至 1.10 美元之間。</p>
</div><p>The company also cited an expected medical benefit ratio of 95.2%—higher than previously anticipated due to ongoing cost pressures in its healthcare segment. Investors were cautioned not to rely on prior earnings guidance, given the continued strain on the company’s health benefits unit.</p>
<div class="lb-trans"><p>該公司還提到了預期的醫療效益比為 95.2%，由於其醫療保健部門持續面臨成本壓力，高於先前預期。投資者被告知不要依賴先前的盈利指引，考慮到公司醫療福利部門持續承受的壓力。</p>
</div><p>CVS is scheduled to release its third-quarter earnings report on November 6, a key date for investors awaiting more clarity on the company’s financial direction.</p>
<div class="lb-trans"><p>西維斯計劃於 11 月 6 日發佈其第三季度財報，這是投資者期待更多瞭解公司財務方向的關鍵日期。</p>
</div><p>The leadership change follows growing pressure from Glenview Capital, a major CVS shareholder, which has been advocating for significant changes at the company.</p>
<div class="lb-trans"><p>此次領導層變動是受到西維斯的主要股東 Glenview Capital 的不斷施壓而進行的，後者一直在倡導對公司進行重大改變。</p>
</div><p>Reports also surfaced last month that CVS’s board was working with strategic advisors to explore various options, including a potential breakup of its insurance and retail divisions.</p>
<div class="lb-trans"><p>上個月也有報道稱，西維斯董事會正在與戰略顧問合作，探討各種選項，包括潛在分拆其保險和零售部門。</p>
</div><p>David Joyner, who previously led CVS’s pharmacy services as president of CVS Caremark, is expected to bring deep industry expertise to the CEO role.</p>
<div class="lb-trans"><p>大衞·喬納此前曾領導西維斯的藥房服務，擔任西維斯凱瑪克（CVS Caremark）總裁，預計他將為 CEO 角色帶來深厚的行業專業知識。</p>
</div><p>Joyner started his career at Aetna in pharmacy benefits and has held several senior leadership positions within CVS.</p>
<div class="lb-trans"><p>喬納在 Aetna 的藥品福利部門開始了他的職業生涯，並在西維斯內擔任過多個高級領導職位。</p>
</div><p>His appointment is seen as a strategic move to navigate the company through its current challenges and unlock future value.</p>
<div class="lb-trans"><p>他的任命被視為一項戰略舉措，旨在引領公司度過當前的挑戰並釋放未來價值。</p>
</div><p>“We believe David’s deep understanding of our integrated business will allow us to tackle the challenges our industry faces and accelerate the operational improvements needed,” said Chairman Roger Farah, who will now assume the role of executive chairman.</p>
<div class="lb-trans"><p>董事長羅傑·法拉表示：“我們相信大衞對我們綜合業務的深刻理解將使我們能夠應對我們行業面臨的挑戰，並加速所需的運營改進。” 法拉將擔任執行董事長。</p>
</div><p>Karen Lynch, who stepped down from her position as CEO, also resigned from the company’s board.</p>
<div class="lb-trans"><p>卡倫·林奇辭去 CEO 職務後，也從公司董事會辭職。</p>
</div><p>Joyner will now take a seat on the board as part of the leadership transition.</p>
<div class="lb-trans"><p>喬納將作為領導層過渡的一部分加入董事會。</p>
</div><p>As CVS works to restore investor confidence and improve profitability, the new leadership under Joyner aims to steer the company through this critical phase of transformation.</p>
<div class="lb-trans"><p>在西維斯努力恢復投資者信心和提高盈利能力的同時，喬納領導下的新領導層旨在引領公司度過這一關鍵的轉型階段。</p>
</div><p>The post CVS stock drops 13% as company replaces CEO Karen Lynch with David Joyner appeared first on Invezz</p>
<div class="lb-trans"><p>文章來源：Invezz，西維斯股價下跌 13%，公司用大衞·喬納取代 CEO 卡倫·林奇</p>
</div>

西維斯股價下跌 13%，公司將 CEO Karen Lynch 替換為 David Joyner